Betamethasone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
bempedoic acid
ATP-Citrate Lyase Inhibitor · Antihyperlipidemic
ATP-Citrate Lyase InhibitorAntihyperlipidemic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- BetamethasoneSevereDatabaseDDInter
- BudesonideSevereDatabaseDDInter
- CinoxacinSevereDatabaseDDInter
- CiprofloxacinSevereDatabaseDDInter
Mechanism
Bempedoic acid is a prodrug that is metabolized to bempedoic acid-CoA, a competitive inhibitor of ATP-citrate lyase (ACL). ACL is a cytoplasmic enzyme that converts citrate to acetyl-CoA, a precursor for de novo cholesterol biosynthesis. By blocking ACL, bempedoic acid reduces hepatic cholesterol synthesis and upregulates LDL receptors on hepatocyte membranes, increasing LDL uptake and catabolism.
Indications
Adjunct to diet and maximally tolerated statin therapy to further lower LDL-C in adults with HeFH or established ASCVDPatients who are statin-intolerant or do not achieve desired LDL-C levels with statins
Dosing
- Adult
- 180 mg orally once daily. Fixed-dose combination with ezetimibe (180 mg bempedoic acid and 10 mg ezetimibe) is also available.
Pharmacokinetics
Onset
Steady-state concentrations reached after 7 days of therapy
Half-life
21 ± 11 h
Metabolism
Prodrug and active metabolite inactivated by UGT2B7 to glucuronide conjugates
Excretion
70% excreted in urine
Contraindications
- Pregnancy (may cause harm to the fetus)
Side effects
Common
Hyperuricemia (can increase risk of gout)Increased serum creatine kinaseIncreased serum creatinineIncreased hepatic transaminases
Serious
- Tendon ruptures
Drug interactions
Budesonide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cinoxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Ciprofloxacin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deflazacort
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Delafloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Dexamethasone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Enoxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Fludrocortisone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Gatifloxacin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Gemifloxacin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Grazoprevir
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about bempedoic acid
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team